EP Mamounas

2.0k citations
49 papers · 1.3k · 1 hit paper · h-index 16

Impact in

  • Cancer Research top 2%
    • Breast Cancer Treatment Studies
  • Oncology top 5%
    • HER2/EGFR in Cancer Research
    • Cancer Treatment and Pharmacology
    • Global Cancer Incidence and Screening

Papers in

  • Cancer Research 45
    • Breast Cancer Treatment Studies 43
    • Cancer Genomics and Diagnostics 4
  • Oncology 28
    • Cancer Treatment and Pharmacology 13
    • HER2/EGFR in Cancer Research 12
    • Cancer Diagnosis and Treatment 4
Co-authors
Norman Wolmark (40 shared papers)J. P. Costantino (21 shared papers)Thomas B. Julian (5 shared papers)Stewart Anderson (8 shared papers)Irene Wapnir (4 shared papers)Sandra M. Swain (2 shared papers)Richard G. Margolese (2 shared papers)Bernard Fisher (2 shared papers)
Journals
Cancer Research (30 papers)Journal of Clinical Oncology (14 papers)Clinical Medicine & Research (1 paper)JNCI Journal of the National Cancer Institute (1 paper)Breast Cancer Research (1 paper)
Partner nations
United StatesSwitzerlandCanada

In The Last Decade

EP Mamounas

49 papers receiving 1.3k citations

EP Mamounas's Hit Papers

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS 2011 · 517 citations
5170+5+10Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2011 JNCI Journal of the National Cancer Institute

Peers

EP Mamounas
Comparison fields: 5 of 61
  • Cancer Research 967
  • Oncology 767
  • Pathology and Forensic Medicine 436
  • Radiation 123
  • Radiology, Nuclear Medicine and Imaging 273
Replace Corrado Tinterri with:
Corrado Tinterri Italy
Bettina Ballardini Italy
Antoine Avril France
Jeffrey R. Harris United States
Boon Chua Australia
S J Schnitt United States
Jane Pettinga United States
Jacques R. Vilcoq France
Philip Meijnen Netherlands
A. Marilyn Leitch United States
EP Mamounas relative to Corrado Tinterri Italy Corrado Tinterri's profile →
Citations per field
00.5×2×3×3.8×
Corrado Tinterri · 1×
Citations per year

Countries citing papers authored by EP Mamounas

Since Specialization
Citations

This map shows the geographic impact of EP Mamounas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EP Mamounas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EP Mamounas more than expected).

Fields of papers citing papers by EP Mamounas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EP Mamounas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EP Mamounas. The network helps show where EP Mamounas may publish in the future.

Co-authors

The 25 scholars most cited alongside EP Mamounas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with EP Mamounas Line = papers co-authored together EP Mamounas links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
JNCI Journal of the National Cancer Institute ·Irene Wapnir, James J. Dignam, Bernard Fisher, EP Mamounas, Stewart Anderson, Thomas B. Julian, Stephanie R. Land, Richard G. Margolese, Sandra M. Swain, J. P. Costantino, Norman Wolmark
Hit paper breakdown →		2011517
2
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
Journal of Clinical Oncology ·Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, Nancy E. Davidson, Charles E. Geyer, Silvana Martino, EP Mamounas, Paulo Kauffman, Norman Wolmark
2007160
3
OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.
Cancer Research ·TB Julian, J. P. Costantino, F.A. Vicini, JR White, RS Cecchini, K. Winter, D.W. Arthur, Robert R. Kuske, R Rabinovitch, DS Parda, EP Mamounas, Curran Wj, Norman Wolmark
201171
4
Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.
Journal of Clinical Oncology ·Thomas B. Julian, J. P. Costantino, Frank A. Vicini, Julia White, K.A De Winter, D.W. Arthur, Robert R. Kuske, Rachel Rabinovitch, David S. Parda, EP Mamounas, Walter J. Curran, Norman Wolmark
201168
5
Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31
Journal of Clinical Oncology ·Soonmyung Paik, C. Kim, Jong‐Hyeon Jeong, Charles E. Geyer, Edward H. Romond, Odille Mejia‐Mejia, EP Mamounas, D. Lawrence Wickerham, J. P. Costantino, Norman Wolmark
200756
6
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clinical Medicine & Research ·EP Mamounas
200342
7
Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)
Cancer Research ·L. Fehrenbacher, RS Cecchini, CE Geyer, Priya Rastogi, J. P. Costantino, JN Atkins, Jonathan Polikoff, J-F Boileau, Louise Provencher, Christopher Stokoe, T Moore, A. Robidoux, Virginia F. Borges, KS Albain, SM Swain, Soonmyung Paik, EP Mamounas, Norman Wolmark
201840
8
Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42
Cancer Research ·EP Mamounas, Hanna Bandos, BC Lembersky, CE Geyer, Louis Fehrenbacher, ML Graham, SL Chia, Adam Brufsky, BT Hennessy, GS Soori, S. R. Dakil, T. E. Seay, JL Wade, EC McCarron, Soonmyung Paik, SM Swain, D. L. Wickerham, Norman Wolmark
201737
9
Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831
Cancer Research ·Edward H. Romond, VJ Suman, J-H Jeong, GW Sledge, CE Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, SM Swain, Eric P. Winer, Gerardo Colón‐Otero, Clifford A. Hudis, Soonmyung Paik, Nancy E. Davidson, EP Mamounas, JA Zujewski, Norman Wolmark, E. González Pérez
201233
10
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.
Journal of Clinical Oncology ·Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, A. Robidoux, J. N. Atkins, Luis Báez, Adam Brufsky, Rita S. Mehta, Louis Fehrenbacher, Eduardo R. Pajon, Frank M. Senecal, Rakesh Gaur, Richard G. Margolese, Paul T. Adams, Howard M. Gross, Sandra M. Swain, EP Mamounas, Joseph P. Costantino, Norman Wolmark
201133
11
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52
Cancer Research ·MF Rimawi, RS Cecchini, Priya Rastogi, CE Geyer, Louis Fehrenbacher, PJ Stella, Zoneddy Dayao, Rachel Rabinovitch, S.H. Dyar, P. Flynn, Luis Báez-Díaz, Soonmyung Paik, SM Swain, EP Mamounas, CK Osborne, Norman Wolmark
201729
12
NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.
Cancer Research ·SM Swain, Joon Jeong, CE Geyer, J. P. Costantino, ER Pajon, L. Fehrenbacher, JN Atkins, Jonathan Polikoff, V. G. Vogel, JK Erban, R. B. Livingston, EA Perez, EP Mamounas, PA Ganz, S. R. Land, Norman Wolmark
200921
13
Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28
Cancer Research ·EP Mamounas, Grace H. Tang, Seungmok Paik, FL Baehner, Q Liu, J-H Jeong, S-R Kim, SM Butler, Farid Jamshidian, DB Cherbavaz, AP Sing, S. Shak, TB Julian, BC Lembersky, D. L. Wickerham, J. P. Costantino, Norman Wolmark
201219
14
Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23
Journal of Clinical Oncology ·Irene Wapnir, Stewart Anderson, EP Mamounas, Charles E. Geyer, J. Hyeon-Jeong, J. P. Costantino, Bernard Fisher, Norman Wolmark
200518
15
Is breast cancer survival improving?: Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000
Sharon H. Giordano, Aman U. Buzdar, Terry L. Smith, EP Mamounas
200417
16
Is boost therapy necessary in the treatment of DCIS?
Journal of Clinical Oncology ·Thomas B. Julian, S. R. Land, Y. Wang, Frank A. Vicini, D.W. Arthur, EP Mamounas, J. P. Costantino, Norman Wolmark
200817
17
S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.
Cancer Research ·AHG Paterson, SJ Anderson, BC Lembersky, Louis Fehrenbacher, CI Falkson, K. King, L. Weir, Adam Brufsky, Shaker R. Dakhil, Thomas E. Lad, Luis Báez-Díaz, JR Gralow, A. Robidoux, EA Perez, Ping Zheng, CE Geyer, SM Swain, J. P. Costantino, EP Mamounas, Norman Wolmark
201114
18
Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.
Journal of Clinical Oncology ·David N. Krag, Stewart Anderson, TB Julian, A Brown, Seth P. Harlow, J. P. Costantino, T. Ashikaga, Donald L. Weaver, EP Mamounas, Norman Wolmark
201013
19
Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)
Cancer Research ·Stefan Aebi, Shari Gelber, István Láng, SJ Anderson, A. Robidoux, M Martín, JWR Nortier, EP Mamounas, CE Geyer, Rudolf Maibach, RD Gelber, Norman Wolmark, Irene Wapnir
201210
20
Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study
Cancer Research ·G. N. Hortobagyi, Steven Shak, GW Sledge, EP Winer, KS Albain, EP Mamounas, DM Jakubowski, VI Petkov, Norman Wolmark
20199

About EP Mamounas

EP Mamounas is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 49 papers that have together received 1.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (43 papers), Advanced Breast Cancer Therapies (18 papers), Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (12 papers), Breast Lesions and Carcinomas (9 papers), Estrogen and related hormone effects (6 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Diagnosis and Treatment (4 papers). The work is most often cited by research in Cancer Research (967 citations), Oncology (767 citations), Pathology and Forensic Medicine (436 citations), Radiation (123 citations) and Radiology, Nuclear Medicine and Imaging (273 citations). EP Mamounas has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Norman Wolmark, J. P. Costantino, Thomas B. Julian, Stewart Anderson, Irene Wapnir, Sandra M. Swain, Richard G. Margolese, Bernard Fisher, Stephanie R. Land and James J. Dignam. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Medicine & Research, JNCI Journal of the National Cancer Institute and Breast Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Corrado TinterriBreakdown of academic impact, for papers by Bettina BallardiniBreakdown of academic impact, for papers by Antoine AvrilBreakdown of academic impact, for papers by Jeffrey R. HarrisBreakdown of academic impact, for papers by Boon ChuaBreakdown of academic impact, for papers by S J SchnittBreakdown of academic impact, for papers by Jane PettingaBreakdown of academic impact, for papers by Jacques R. VilcoqBreakdown of academic impact, for papers by Philip MeijnenBreakdown of academic impact, for papers by A. Marilyn Leitch